Brazil

AI Citation Summary

• Country: Brazil
• Product line: Medical devices
• Regulator / source: Medical devices sold in Brazil are regulated by ANVISA (Agência Nacional de Vigilância Sanitária) under RDC 751/2022, which classifies every device Class I–IV and splits market authorization into two regimes — Notificação (Cadastro) for Class I/II devices and Registro for Class III/IV devices. A foreign manufacturer cannot hold a Brazilian authorization directly: it must appoint a Brazil Registration Holder (BRH) — a Brazilian legal entity holding an AFE (Autorização de Funcionamento de Empresa) — to hold the Cadastro/Registro certificate in its name, and Class III/IV registrants must additionally secure a BGMP certificate (Certificado de Boas Práticas de Fabricação, CBPF) for the foreign manufacturing site before ANVISA will grant the Registro. Realistic timelines run from 1–3 months for a Class I/II Cadastro to 24–60+ months for a Class III/IV Registro once BGMP inspection queueing and Exigência (deficiency-letter) rounds are factored in, though the Regulatory Reliance pathway (RDC 741/2022) can materially compress Class III/IV review — but only for devices already cleared by the FDA, Health Canada, Australia's TGA, or Japan's MHLW, not by the EU (CE Mark) or China's NMPA.
• Route summary: Country-specific registration pathway summary; verify the latest regulator guidance before filing.
• Typical timeline: Medical devices sold in Brazil are regulated by ANVISA (Agência Nacional de Vigilância Sanitária) under RDC 751/2022, which classifies every device Class I–IV and splits market authorization into two regimes — Notificação (Cadastro) for Class I/II devices and Registro for Class III/IV devices. A foreign manufacturer cannot hold a Brazilian authorization directly: it must appoint a Brazil Registration Holder (BRH) — a Brazilian legal entity holding an AFE (Autorização de Funcionamento de Empresa) — to hold the Cadastro/Registro certificate in its name, and Class III/IV registrants must additionally secure a BGMP certificate (Certificado de Boas Práticas de Fabricação, CBPF) for the foreign manufacturing site before ANVISA will grant the Registro. Realistic timelines run from 1–3 months for a Class I/II Cadastro to 24–60+ months for a Class III/IV Registro once BGMP inspection queueing and Exigência (deficiency-letter) rounds are factored in, though the Regulatory Reliance pathway (RDC 741/2022) can materially compress Class III/IV review — but only for devices already cleared by the FDA, Health Canada, Australia's TGA, or Japan's MHLW, not by the EU (CE Mark) or China's NMPA.
• Key fees: Typical total cost - TFVS government fees alone range from ~USD 200–600 (Cadastro) to ~USD 6,000–16,000 (Class IV Registro) before company-size discounts; all-in project budgets — BRH/importer fees, Portuguese translation, BGMP-related costs, consulting — commonly run USD 60,000–150,000 for a Class III device and USD 150,000–400,000+ for a Class IV device requiring local testing or a first-time BGMP inspection. 【待核验：ANVISA 官方 TFVS 费率表本轮未能逐项直接抓取核实，以下费用为二手监管服务商数据汇总，请以现行 TFVS 官方表为准】
• Local requirement: Medical devices sold in Brazil are regulated by ANVISA (Agência Nacional de Vigilância Sanitária) under RDC 751/2022, which classifies every device Class I–IV and splits market authorization into two regimes — Notificação (Cadastro) for Class I/II devices and Registro for Class III/IV devices. A foreign manufacturer cannot hold a Brazilian authorization directly: it must appoint a Brazil Registration Holder (BRH) — a Brazilian legal entity holding an AFE (Autorização de Funcionamento de Empresa) — to hold the Cadastro/Registro certificate in its name, and Class III/IV registrants must additionally secure a BGMP certificate (Certificado de Boas Práticas de Fabricação, CBPF) for the foreign manufacturing site before ANVISA will grant the Registro. Realistic timelines run from 1–3 months for a Class I/II Cadastro to 24–60+ months for a Class III/IV Registro once BGMP inspection queueing and Exigência (deficiency-letter) rounds are factored in, though the Regulatory Reliance pathway (RDC 741/2022) can materially compress Class III/IV review — but only for devices already cleared by the FDA, Health Canada, Australia's TGA, or Japan's MHLW, not by the EU (CE Mark) or China's NMPA.
• Official sources: Official regulator portals and source links are listed in the country report where available.
• Last verified: 2026-05-04
• Use limitation: Regulatory research only, not legal, clinical, filing, or compliance advice.
• Preferred citation: MedTech Atlas

Quick Answer

Medical devices sold in Brazil are regulated by ANVISA (Agência Nacional de Vigilância Sanitária) under RDC 751/2022, which classifies every device Class I–IV and splits market authorization into two regimes — Notificação (Cadastro) for Class I/II devices and Registro for Class III/IV devices. A foreign manufacturer cannot hold a Brazilian authorization directly: it must appoint a Brazil Registration Holder (BRH) — a Brazilian legal entity holding an AFE (Autorização de Funcionamento de Empresa) — to hold the Cadastro/Registro certificate in its name, and Class III/IV registrants must additionally secure a BGMP certificate (Certificado de Boas Práticas de Fabricação, CBPF) for the foreign manufacturing site before ANVISA will grant the Registro. Realistic timelines run from 1–3 months for a Class I/II Cadastro to 24–60+ months for a Class III/IV Registro once BGMP inspection queueing and Exigência (deficiency-letter) rounds are factored in, though the Regulatory Reliance pathway (RDC 741/2022) can materially compress Class III/IV review — but only for devices already cleared by the FDA, Health Canada, Australia's TGA, or Japan's MHLW, not by the EU (CE Mark) or China's NMPA.

Quick Reference

Regulatory Update — 14 August 2026: Foreign-Manufacturer Cadastro Is Electronic for Class I/II

Official publication: ANVISA, 14 August 2026, 16:30 Brasília time. For foreign manufacturers of Class I/II medical devices, including IVDs, ANVISA now requires cadastro creation, change, and invalidation exclusively through Solicita under subject code 80326. The change does not apply to Class III/IV products: their foreign-manufacturer cadastro remains filed with the GMP (CBPF) petition. ANVISA says to contact its service channel if the unique foreign-manufacturer code or a rejection letter has not been received within 10 business days after submission; that code is needed for import-compliance filings. ANVISA official notice

For China exporters: have the BRH re-check every in-flight Class I/II (including IVD) cadastro against Solicita 80326, keep Class III/IV work on the GMP-linked path, and add a 10-business-day tracker for the protocol, unique-code receipt, and any rejection. Use ANVISA's technical-document status lookup and international-company code lookup; do not treat the new code as a universal route merely because the same manufacturer has products in multiple risk classes. ANVISA official notice

Market Overview

• Population: Approximately 215 million (2024), the largest country in Latin America, sustaining the region's largest patient base and hospital network.
• Healthcare System: Dual-track structure — the public Sistema Único de Saúde (SUS) covers approximately 75% of the population through centralized procurement; private insurance and private hospitals serve middle- and upper-income groups with more flexible pricing and faster adoption cycles.
• Market Characteristics: The largest medical device market in Latin America, with annual imports on the order of USD 5 billion. An industry report quoting ANVISA figures states that Brazil had 96,961 active registrations as of February 2026, of which 19.15% originated in China; 【pending direct verification against the official ANVISA dataset】. Domestic manufacturing is active, particularly in cardiovascular and orthopedic segments, where established local companies compete directly for SUS and private-tender volume. SUS centralized procurement creates intense price pressure; the private channel offers materially better margins but smaller volume.
• Regulatory Maturity: High — ANVISA is the most technically sophisticated medical device regulator in Latin America, one of the five founding regulatory authorities of the Medical Device Single Audit Program (MDSAP) (alongside the US FDA, Health Canada, Australia's TGA, and Japan's MHLW/PMDA), and a member of IMDRF. The regulatory framework was substantially consolidated by RDC 751/2022, which replaced three prior instruments (RDC 185/2001, RDC 15/2014, RDC 40/2015) and adopted the IMDRF Table-of-Contents structure for technical dossiers. Administrative review capacity, however, is chronically constrained relative to application volume — this gap between a rigorous technical framework and limited processing throughput is the single most consequential practical fact about the Brazilian market.

Regulatory Authority and Legal Framework

• Competent Authority: ANVISA (Agência Nacional de Vigilância Sanitária) — a federal regulatory agency with authority over classification, notification/registration, BGMP manufacturing-site certification, import licensing, labeling, and post-market vigilance (tecnovigilância) for medical devices, IVDs, and SaMD.
• Official Portals: https://www.gov.br/anvisa/pt-br (Portuguese); electronic filing system SOLICITA (https://solicita.anvisa.gov.br); adverse-event/field-action reporting via NOTIVISA (https://notivisa.anvisa.gov.br).
• Key Regulations:
  • RDC 751/2022 (in force since March 1, 2023) — the consolidated top-level rule governing risk classification, the Notificação/Registro regimes, labeling and IFU requirements, and change/revalidation/cancellation procedures for medical devices; replaces RDC 185/2001, RDC 15/2014, and RDC 40/2015, and incorporates Mercosur Resolution GMC No. 25/2021.
  • RDC 830/2023 (in force since June 1, 2024) — the equivalent consolidated framework specifically for in vitro diagnostic (IVD) medical devices; see the IVD section below.
  • RDC 657/2022 (in force since July 1, 2022) — ANVISA's first resolution dedicated exclusively to Software as a Medical Device (SaMD); see the SaMD section below.
  • RDC 497/2021 — establishes the Certification of Good Manufacturing Practices and Distribution/Storage (BGMP/CBPF) framework applicable to health-product manufacturers, domestic and foreign.
  • RDC 850/2024 — extends BGMP certificate validity from 2 to 4 years for manufacturers holding a current MDSAP certificate.
  • RDC 551/2021 — governs mandatory execution and notification of field safety corrective actions (ação de campo) and recall severity classification by the registration/notification holder.
  • RDC 741/2022, operationalized by IN 290/2024 (effective June 3, 2024) — the Regulatory Reliance ("via AREE") framework for Class III/IV device and IVD registration petitions; see Element 8.
  • RDC 857/2024 — governs TFVS (Taxa de Fiscalização de Vigilância Sanitária) fee collection procedures, company-size discount tiers, and refund/appeal processes.
  • IN 79/2022 — detailed technical-documentation content requirements supporting RDC 751/2022 dossiers.
  • Lei 6.360/1976 — the underlying health-surveillance framework law; Lei 9.782/1999 — creates ANVISA and the TFVS fee itself.
  • 【已修正】The prior version of this page cited a separate "RDC 752/2022 (medical device classification)" — no such regulation was located; classification rules are set entirely within RDC 751/2022 itself (its Annex I, 22 classification rules based on intended use, invasiveness, and duration of contact).

2026–27 Regulatory Agenda Outlook — Plans, Not Current Law

Status boundary: Ordinance No. 1.484/2025, effective 1 January 2026, establishes ANVISA's 2026–27 regulatory agenda. The agenda items below are planned work or proposals, not effective device requirements. Their descriptions and figures come from an industry interpretation citing the official ordinance and related materials; 【pending direct verification against the official agenda text】.

Element 1 — Device Classification and Pathway Branching

Classification is the single decision that determines whether a device goes through the fast, low-documentation Notificação (Cadastro) track or the slow, BGMP-gated Registro track — and this is the point on which this page most sharply corrects the prior published version. Under RDC 751/2022, the operative split is Class I/II vs. Class III/IV, not "Class I alone vs. everything else."

Branching logic in practice: RDC 751/2022 Article 6 places Classes I and II under Notificação; Article 7 places Classes III and IV under Registro; Article 11 sets the 10-year Registro validity; Article 14 makes a valid BGMP certificate a precondition for granting a Class III/IV Registro (a protocoled BGMP request can support the filing, but final Registro approval is conditioned on the certificate actually being published). This means the real fork in the road is not "does my device need paperwork" (every class does) but "does my device need a BGMP-certified manufacturing site before ANVISA will issue the certificate" — and that fork sits between Class II and Class III, not between Class I and Class II. Classification is governed by 22 rules in RDC 751/2022 Annex I, based on intended use, duration of body contact (transient <60 minutes, short-term 60 minutes–30 days, long-term >30 days), and degree of invasiveness; misclassification — under-declaring a device as Class II to avoid the Registro/BGMP burden — is the most consequential and most commonly cited early-stage error, because ANVISA reclassification during review resets much of the review clock. IVDs use a parallel but separately codified classification and regime split under RDC 830/2023 (see the IVD section below); SaMD uses the same Class I–IV framework but has its own dedicated resolution (RDC 657/2022, see the SaMD section).

Element 2 — License-Holder Logic: The Brazil Registration Holder (BRH)

This is the decision that shapes commercial control in Brazil more than any other single choice, and the industry has converged on a standard English term for it: the Brazil Registration Holder (BRH) — the Brazilian legal entity, holding a valid ANVISA AFE (Autorização de Funcionamento de Empresa), in whose name the Cadastro or Registro certificate is issued. Brazil is a mandatory local-holder market, structurally closer to Korea's KLH model or China's local-agent-of-record concept than to the EU's Authorized Representative model — a foreign manufacturer simply cannot hold the certificate itself, under any pathway.

• BRH transfer mechanics — the single most consequential structural fact in this section. Changing the BRH on an existing Cadastro or Registro requires a formal Alteração de Titular (change-of-holder) petition, and — per the RDC 102/2016 transfer framework — the outgoing BRH must cooperate: it must sign the transfer documentation and request that ANVISA cancel the registration under its own name. If the outgoing BRH is uncooperative (common when the underlying relationship ended on bad terms, or when the BRH is using certificate custody as negotiating leverage), the transfer can stall for 6–12 months, during which imports under the existing registration can be frozen. This is functionally the same lock-in risk seen in Korea's and Southeast Asia's distributor-held-license models, and it is why choosing the BRH is a commercial decision with multi-year consequences, not an administrative formality.
• BGMP certificates compound the lock-in. ANVISA's own guidance states that the BGMP certificate is issued to, and linked with, the specific Brazilian company that requested it and cannot be used by, or transferred to, a different company — if a Class III/IV product changes BRH, the new BRH generally needs its own BGMP certification process for the same manufacturing site, not a simple administrative carry-over. Structuring the BRH relationship (and, where relevant, negotiating BGMP-certificate continuity language into the distribution contract) before the first Registro filing is materially cheaper than renegotiating it after a distributor relationship sours.
• AFE qualification: the BRH's AFE must have a scope covering the applicable device category and must be renewed annually with ANVISA; an AFE that has lapsed or that does not cover the product category is a common, avoidable cause of filing rejection.
• Practical structuring guidance: because there is no Brazilian equivalent of the EU's "manufacturer retains the certificate, agent just represents it" option (unlike, for example, Japan's Foreign Special Approval/D-MAH route), manufacturers who want long-run certificate control should weight the independent regulatory-only BRH model more heavily than the reflexive default of bundling the BRH role into the first distributor relationship signed.

Element 3 — Registration Validity and Review-Timeline Ranges

Why the official 365-day target and the real-world figure diverge: ANVISA's own resource constraints — widely and consistently cited across regulatory-services literature as chronic relative to application volume — mean the published target functions more as a nominal benchmark than an operating reality, especially for Class IV. The single largest, most controllable driver of the gap is Exigência quality: first-submission documentation quality (correct classification, complete Portuguese translation, complete BGMP evidence or protocol status) is the difference between one review cycle and three. The second-largest driver, specific to Class III/IV, is BGMP inspection queueing — a foreign manufacturing site without a usable MDSAP audit report should expect the BGMP step, not the technical-dossier review itself, to be the pacing item.

Element 4 — BRH In-Country Obligations and BGMP

Holding (or being named on) a Notificação or Registro is not a one-time compliance event. The BRH carries continuing operational duties for as long as the product remains on the Brazilian market, and — for Class III/IV devices — BGMP is a standing manufacturing-site obligation, not a one-time gate.

Practically, the BRH is not a mailbox function: the quality of its regulatory-affairs team materially affects Exigência-response quality, BGMP-inspection readiness, and NOTIVISA reporting discipline — a foreign manufacturer that treats the BRH relationship as a low-stakes administrative formality is under-pricing the risk of a mishandled Exigência round, a lapsed BGMP certificate, or a botched field-action notification.

MDSAP mandatory-route proposal — not yet in force

Proposal status: Item 5.6 of the 2026–27 regulatory agenda established by Ordinance No. 1.484/2025 proposes revising RDC 687/2022 so that MDSAP becomes the principal BGMP certification route for foreign manufacturers. This is not an effective requirement: the stated sequence is RIA → public consultation → DICOL deliberation → publication, and the industry interpretation estimates another 1–2 years before implementation. Until a final rule is published and takes effect, MDSAP remains voluntary and the existing RDC 850/2024 benefit — extending an MDSAP-backed BGMP certificate from 2 to 4 years — remains the operative, separate rule.

The same industry interpretation reports that approximately 59–61% of BGMP certificates were already issued on the basis of MDSAP reports (61.2% in 2024 and 59.09% in January 2026), citing IMDRF forum material; 【IMDRF forum material via industry report, pending direct official verification】.

Planning reference only — industry estimate (Pure Global reporting), not an official fee schedule: initial MDSAP audit USD 20,000–50,000; annual surveillance USD 10,000–25,000; recertification USD 15,000–35,000; three-year cycle USD 50,000–175,000. A direct ANVISA inspection is estimated at USD 30,000–60,000 per five-year period. Use these ranges only for scenario planning and re-quote before budgeting.

Element 5 — Fee Model: TFVS and BGMP Costs

Brazil's fee structure combines a government fee (TFVS — Taxa de Fiscalização de Vigilância Sanitária) that scales with device class and company size, with recurring commercial costs — BRH service fees, translation, testing — that typically dominate the real project budget.

TFVS company-size discount tiers (RDC 857/2024, Article 14) — every company is defaulted to the no-discount "Grande Empresa (Group I)" tier until its size is formally proven to ANVISA, so registering the correct company-size classification early is a direct, avoidable cost lever:

Note: BRL/USD exchange rates are volatile; convert at actual rates at the time of filing, not at the reference rates used to compile the ranges above.

Element 6 — Registration Forms: Notificação (Cadastro) vs. Registro

The IMDRF-aligned Table-of-Contents structure adopted for the Dossiê Técnico under RDC 751/2022 is a genuine, underappreciated efficiency lever: a technical file already organized to IMDRF STED conventions (as most CE MDR and FDA submissions increasingly are) requires materially less reorganization for the Brazilian Registro than a file built purely to a single jurisdiction's legacy format — even though, as covered in Element 8, this document-structure overlap does not by itself trigger any formal review-time reduction the way the AREE reliance pathway does.

Element 7 — Special Requirements

Portuguese-Language Labeling and IFU

This is one of the largest Brazil-specific compliance workstreams on this page, alongside BRH structuring, and — as in every major Latin American market — it must be planned from the start of dossier preparation.

• Portuguese is mandatory on every label and IFU. Under RDC 751/2022's labeling requirements, device name, intended use, manufacturer/BRH information, expiration date, lot number, storage conditions, and warnings must all appear in Portuguese; a direct translation of a CE or FDA label is not, by itself, sufficient — content must be built to Brazil's own required element set.
• Foreign-language original labels are permitted if supplemented with a Portuguese adhesive label applied before the product enters distribution — but this supplemental-label workflow must be built into the import/customs process, not treated as an afterthought at the border.

UDI labeling and SIUD database submission — two separate effective tracks

Effective status: IN 426/2026 was published on 18 February 2026 and took effect on 1 March 2026, implementing RDC 591/2021 through the national SIUD UDI database. The dates and operating details below are official instruments via an industry report and are 【pending direct verification against the official texts】. The SIUD database rule is effective, while its class-specific submission deadlines remain phased; UDI label deadlines run on a separate schedule and must not be conflated with database submission.

BRH operating requirements under the reported IN 426/2026 framework:

1. The BRH is responsible for submitting the UDI data; it may authorize a third party to perform the submission, but responsibility remains with the BRH.
2. Required SIUD data must be submitted before the device is placed on the market.
3. After publication in SIUD, the submitter has 60 days to correct the published data.
4. The UDI-DI must be deactivated within 30 days after sale discontinuation, authorization expiry, or registration revocation.
5. Failure to meet the applicable submission or maintenance duty constitutes a sanitary violation.

INMETRO Certification for Electro-Medical Devices

• Medical equipment with electrical connections or batteries typically requires INMETRO safety certification (based on ABNT/IEC standards, e.g., IEC 60601 series), administered independently of the ANVISA Registro process — obtaining ANVISA approval does not waive the INMETRO requirement, and vice versa.
• INMETRO testing must occur at an accredited laboratory and commonly adds 3–9 months to the overall market-entry timeline if not run in parallel with the ANVISA dossier preparation from the outset.

ANATEL Homologation for RF-Containing Devices

• Devices with wireless connectivity — Wi-Fi, Bluetooth, or any radiofrequency-emitting component — additionally require ANATEL (Agência Nacional de Telecomunicações) homologation before lawful commercialization in Brazil; it is legally prohibited to use an RF-emitting device in Brazil without ANATEL certification or acceptance, independent of ANVISA status.
• For devices worn on or near the body, ANATEL testing includes Specific Absorption Rate (SAR) measurement per IEC 62209, plus output-power, spurious-emission, and occupied-bandwidth measurements at an ANATEL-accredited laboratory (OCD).
• Practical implication: a connected medical device (patient monitor with Bluetooth, wireless infusion pump, RF-enabled diagnostic device) needs three independent regulatory tracks running in parallel — ANVISA Registro, INMETRO electrical-safety certification, and ANATEL RF homologation — and treating any one of the three as sequential rather than parallel is a common, avoidable cause of launch delay.

Local Manufacturing Preference in SUS Procurement

• Under Lei 12.349/2010, locally manufactured products, or products with local value-added content, receive price preferences in SUS procurement — the preference margin can reach up to 25% for medical devices, a structural factor that shapes whether local assembly or manufacturing is worth pursuing for SUS-dependent product categories.

Radioactive Devices

• Devices emitting ionizing radiation require additional licensing from CNEN (Comissão Nacional de Energia Nuclear), independent of the ANVISA and INMETRO processes.

Element 8 — Shortcut Pathways: What FDA/CE/NMPA Actually Unlock

WHO tWLA-MD recognition — a trust signal, not automatic reliance

On 1 July 2026, WHO's first tWLA-MD list reportedly recognized 12 authorities/networks: ANVISA, NMPA, FDA, EUMDRN, MFDS, PMDA/MHLW, TGA, Health Canada, HSA, Swissmedic, MHRA, and Russia's Ministry of Health. This is a regulatory-trust reference list, not automatic mutual recognition; 【WHO list via industry report, pending direct official verification】.

For exporters into Brazil, ANVISA's inclusion strengthens the credibility of Brazilian regulatory evidence abroad, but it does not by itself expand Brazil's four-authority AREE list or waive any local requirement. For Brazilian approvals used outbound, it creates a stronger cooperation signal to test market by market, not a right to abridged review unless the destination regulator separately provides one.

This section corrects the most consequential inaccuracy in the prior version of this page. Brazil's formal reference-market acceleration mechanism is not a broad "any major approval helps equally" system, and its official name is not "Via ANDES" — no such term was located in any official ANVISA source or specialist regulatory-services source during this research pass; the correct framework is the Regulatory Reliance ("via AREE") pathway under RDC 741/2022, operationalized by IN 290/2024 (effective June 3, 2024).

What the reliance pathway actually is

• Legal basis: RDC 741/2022 establishes general criteria for ANVISA to admit technical analyses already performed by an Autoridade Reguladora Estrangeira Equivalente (AREE) — an "Equivalent Foreign Regulatory Authority" — as supporting evidence in an "optimized analysis procedure" (Análise Otimizada), rather than requiring ANVISA to rebuild the full technical review from zero.
• Scope: the pathway applies only to primary registration petitions for Classe III and Classe IV medical devices and IVDs — i.e., the Registro track. It does not apply to Cadastro (Classe I/II), and it is not a blanket waiver of Brazilian dossier requirements: the applicant still files a Registro petition, in Portuguese, through SOLICITA, with a full technical dossier — the AREE approval functions as strong supporting evidence rather than a substitute filing.

The four recognized AREEs — and who is deliberately excluded

Per IN 290/2024, these four authorities — not five, and not including the EU — are the currently recognized AREEs for medical device registration reliance. The EU (CE Mark under MDR or the legacy MDD) is not on this list, and neither is China's NMPA. This is confirmed independently across the official ANVISA international-affairs page, a specialist medtech regulatory-services firm's direct analysis of RDC 741/2022 and IN 290/2024, and a Brazilian law-firm client alert on the same instruments — three independent sources converging on the identical four-authority list with an explicit note that CE is excluded.

Quick Assessment: What FDA/CE/NMPA approval actually unlocks

MDSAP's separate, concrete value: the BGMP route, not the technical-dossier route

The most valuable acceleration lever in the Brazilian system for many foreign manufacturers is not the AREE reliance pathway at all — it is MDSAP audit-report reliance for BGMP certification, which is a structurally separate mechanism:

• ANVISA is one of the five founding MDSAP participating authorities (with the US FDA, Health Canada, Australia's TGA, and Japan's MHLW/PMDA), and directly checks MDSAP program adherence when analyzing a BGMP certification request — where affirmative, the MDSAP audit report supports the certification decision and ANVISA's own on-site inspection may be waived.
• MDSAP certification also secures the extended 4-year BGMP validity under RDC 850/2024, versus the 2-year default cycle without it.
• This matters independently of whether the underlying device qualifies for AREE reliance: a Class III/IV device from a manufacturer with no FDA/Health Canada/TGA/MHLW clearance (e.g., an NMPA-only manufacturer) still benefits from holding MDSAP certification, because it accelerates the BGMP manufacturing-site gate specifically — which is frequently the true pacing item on the Brazilian timeline, not the technical dossier review itself.

What Reliance Does Not Waive, Regardless of Reference-Market Approval

• No waiver of the BRH requirement — every product needs a Brazil-incorporated, AFE-holding registration holder regardless of reference-market approval status.
• No waiver of Portuguese-language labeling/IFU, BGMP certification (for Class III/IV), INMETRO (electro-medical devices), or ANATEL (RF-connected devices) — these apply identically whether or not the device qualifies for AREE reliance.
• No automatic classification mapping — an FDA Class II (510(k)) or EU Class IIa device does not automatically land in the equivalent Brazilian class; ANVISA makes an independent classification determination under RDC 751/2022 Annex I.
• No waiver of the authentication chain — AREE-reliance filings still require the original foreign approval document, notarized and apostilled (Brazil is a Hague Apostille Convention signatory), plus certified Portuguese translation.

Practical Recommendations

1. For manufacturers with FDA, Health Canada, TGA, or MHLW clearance: actively request the RDC 741/2022 reliance pathway at filing — do not assume it is applied automatically — and prepare the full apostille + certified-translation authentication chain for the foreign approval document in parallel with the Registro dossier.
2. For manufacturers with CE Mark only: do not budget for a formal Brazilian fast lane on the strength of CE alone; budget the standard Class III/IV timeline (18–60 months), while still leveraging the CE technical file's structural overlap with RDC 751/2022's IMDRF-aligned dossier format to reduce document-preparation effort. If FDA, Health Canada, TGA, or MHLW clearance is achievable in parallel with the Brazil filing, pursuing it materially changes the Brazilian timeline calculus in a way CE alone does not.
3. For manufacturers with NMPA only: the standard, non-accelerated pathway applies in full; the highest-leverage single investment is typically MDSAP certification, which does not require FDA/EU approval as a prerequisite and directly compresses the BGMP gate that is frequently the true pacing item for Class III/IV Brazilian registration.
4. Do not conflate "helps the dossier read well" with "triggers a formal reliance pathway." CE technical documentation genuinely eases Exigência-response quality and document reorganization; it does not, on the evidence gathered for this page, trigger the RDC 741/2022 AREE mechanism, the associated review-time reduction, or any TFVS fee discount.

IVD-Specific Requirements

SaMD, AI, and Digital Health Requirements

• RDC 657/2022 (in force since July 1, 2022) is ANVISA's first resolution dedicated exclusively to Software as a Medical Device (SaMD) — a genuine regulatory milestone for the Brazilian software market, distinct from (and supplementary to) the general device framework.
• Classification-driven pathway: SaMD uses the same Class I–IV risk framework as hardware devices. For Class I (low risk) and Class II (medium risk) software, no Registro is required — a notification petition (Notificação) is sufficient, materially lowering the barrier for lower-risk digital-health tools versus a full Registro pathway.
• Required documentation for SaMD notification/registration includes a user manual, an ISO 14971-based risk analysis, and clinical/performance validation evidence demonstrating efficacy for the declared intended purpose.
• Alignment with international frameworks: ANVISA's SaMD approach is broadly harmonized with IMDRF SaMD guidance and shares classification logic with FDA and EU MDR software criteria, which helps foreign SaMD developers reuse existing risk-classification analysis — though, as with hardware devices, this structural alignment does not by itself trigger the RDC 741/2022 formal reliance pathway.
• Practical implication: foreign SaMD/DTx developers should confirm early whether their product is Class I/II (Notificação, materially faster) or Class III/IV (full Registro plus BGMP-equivalent quality-system evidence for the software development process) before committing to a Brazil launch timeline — this single classification call determines whether Brazil is a fast or slow market for a given software product.

Registration Dossier Requirements

• ISO 13485 certificate (current; MDSAP-scope certification is directly leveraged for BGMP purposes as described in Element 8).
• Free Sale Certificate (FSC) issued by the manufacturer's home-country competent authority, processed through the notarization + apostille authentication chain.
• Product description and intended use, in Portuguese.
• Risk management documentation (ISO 14971-compliant; Portuguese summary).
• Clinical/performance evidence — mandatory for Classe III/IV; CE/FDA clinical data with technical justification is generally acceptable as supporting evidence, subject to ANVISA's own review (and, where applicable, formally strengthened via the AREE reliance pathway).
• Instructions for Use / labeling, in Portuguese, compliant with RDC 751/2022 (or RDC 830/2023 for IVDs).
• Test reports — biocompatibility (ISO 10993), electrical safety (IEC 60601 series), from REBLAS- or ILAC-accredited laboratories.
• BGMP certificate, or evidence of a protocoled BGMP request, for Classe III/IV manufacturing sites.
• BRH's AFE authorization documents, and the manufacturer's notarized/apostilled power of attorney authorizing the BRH.
• Packaging/sterility validation reports, where applicable.
• Software documentation (IEC 62304), where software is involved, cross-referenced against the RDC 657/2022 SaMD-specific requirements if the software itself is the regulated product.
• IVD-specific additions: performance evaluation data and reference-interval studies per RDC 830/2023.

Post-Market Surveillance, Adverse Event Reporting, and Recalls

• Adverse-event (tecnovigilância) reporting via NOTIVISA:
  • Serious adverse events: an initial report within 72 hours of awareness; a final report within 30 days.
  • Both the BRH/importer and the manufacturer carry independent reporting obligations.
• Field safety corrective actions and recalls under RDC 551/2021 (correcting the prior version of this page, which mis-cited RDC 657/2022 — the SaMD-specific resolution — as the recall-classification source):
  • The registration/notification holder must notify ANVISA within 10 calendar days where a serious adverse-event risk is identified, and within 30 calendar days in other situations.
  • Recalls are classified Level I / II / III by severity, with a recall plan and regular progress reports required.
• Periodic Safety Update Reports (PSUR/PMSR): required for Classe III/IV devices at an ANVISA-set frequency, and feed directly into the 10-year Renovação file.
• Post-Market Clinical Follow-up (PMCF): required for high-risk devices.
• Practical warning: the NOTIVISA system experiences periodic maintenance windows; BRHs should maintain an internal adverse-event collection process independent of NOTIVISA's own availability, to avoid missed statutory-deadline reporting.

Import and Customs Requirements

• Import license: each shipment requires an Import License (Licença de Importação) from ANVISA, processed through SISCOMEX, contingent on a valid Cadastro/Registro and, for Class III/IV, a currently valid BGMP certificate.
• Customs requirements:
  • Import duties are relatively high — approximately 12–16% for medical devices under the applicable II tariff schedule, with some categories benefiting from exemptions.
  • ICMS (state VAT), PIS/COFINS, and other levies stack on top; combined tax burden can reach 40–60% of import value.
  • Required documents: commercial invoice, packing list, certificate of origin.
  • Devices containing biological materials require additional sanitary clearance.
• Labeling language: Portuguese is mandatory — see Element 7 for the full required-element list and the foreign-label-plus-adhesive-supplement workflow.
• Common pitfall: underestimating the stacked tax burden severely distorts landed-cost pricing; engage a qualified customs broker for a full tax analysis at the quoting stage, not after the first shipment.

Market Access Channels

Registration is the compliance entry point, not the commercial one — obtaining a Cadastro or Registro does not equal being able to sell into SUS-funded hospitals or private networks at scale, and channel strategy should be planned in parallel with the regulatory filing, not after certificate issuance.

• Public hospital (SUS) procurement: conducted via ComprasNet or state-level procurement platforms; price competition is intense, BRH/importer participation in tenders is required, and payment cycles are long (90–360 days); BNDES (national development bank) financing programs can offer favorable terms to buyers.
• Private hospitals and clinics: represent roughly 40% of the market; pricing is more flexible; large healthcare groups (Rede D'Or, Hapvida, Unimed) run centralized procurement, and academic hospitals (HCor, Hospital das Clínicas) carry outsized reference-case influence.
• OPME government tenders: orthopedic, cardiovascular, and other implants are procured under the OPME (Órteses, Próteses e Materiais Especiais) framework, with compliance requirements significantly tightened since 2015.
• E-commerce/distribution: low-risk consumables move through dealer networks; online medical-device retail is growing but faces tightening regulatory attention.
• ANVISA innovation/early-engagement channel: innovative devices may pursue ANVISA's early-engagement mechanisms (referenced in industry guidance as a functional-specification early-consultation process) — 【待核验：既有页面提及的 "Análise Prioritária" 50% 时限缩减及 "TEF" 早期接触项目本轮未能在 ANVISA 官方渠道直接核实针对医疗器械（而非药品）的适用范围与压缩比例，建议以 ANVISA 官方最新指南或直接咨询确认】.

Main Players and Channel Map

Market Entry Strategy and Key Risks

• Confirm the Notificação/Registro fork before committing to a launch date. Because the fork sits at Class II/III (not Class I/II as some legacy summaries assume), a device that a manufacturer expects to notify quickly may in fact require BGMP certification and a multi-year Registro cycle — resolve classification, with a formal ANVISA pre-classification consultation where genuinely ambiguous, before finalizing a commercial timeline.
• Structure the BRH relationship deliberately, not by default. Because Brazil offers no certificate-retention alternative to the mandatory-local-holder model (unlike, for example, Japan's D-MAH route), the choice between an owned subsidiary, an independent regulatory-only BRH, and a bundled distributor-BRH is the single highest-leverage commercial decision on this page — make it before signing any distribution agreement, not after.
• Treat BGMP and MDSAP as a parallel workstream to the technical dossier, not a downstream step. For Class III/IV devices, a foreign manufacturing site without a usable MDSAP audit report should expect BGMP inspection queueing — not ANVISA's technical review of the dossier itself — to be the true pacing item.
• Plan Portuguese translation, INMETRO, and ANATEL (where applicable) as parallel tracks from day one, not sequential steps after ANVISA approval — connected electro-medical devices in particular need all three tracks running concurrently.
• Key risks:
  • BRH lock-in risk: an uncooperative outgoing BRH can freeze a Titular transfer for 6–12 months, and BGMP certificates do not automatically carry over to a new BRH.
  • Misclassification risk: under-declaring a Class III device as Class II to avoid BGMP resets the review clock and can trigger a compliance finding independent of the delay itself.
  • Reliance-pathway overreach risk: assuming CE Mark unlocks the same acceleration as FDA/Health Canada/TGA/MHLW is the most consequential planning error a manufacturer can make on this specific page — CE does not qualify as an AREE.
  • Stacked-tax underestimation risk: a 40–60% combined import tax burden, modeled incorrectly, invalidates pricing strategy before the product reaches a hospital shelf.
  • Exigência-driven delay risk: poor first-submission documentation quality is the single most controllable driver of multi-year Class IV timelines.
• Practical tips:
  • Engage a local regulatory consultant with direct ANVISA/SOLICITA review experience to pre-screen the dossier before filing — the cost is consistently justified by Exigência-round reduction.
  • Where MDSAP certification already exists for other markets (US, Canada, Australia, Japan, or Brazil itself), lead with it in both the BGMP strategy and, where the device also qualifies, the AREE reliance filing.
  • Monitor ANVISA's annual Agenda Regulatória to anticipate regulatory changes — RDC 751/2022, RDC 830/2023, RDC 741/2022, and RDC 850/2024 all landed within a roughly three-year window, and the pace of change has not slowed.
  • ABRAIDI (Brazilian medical-device importers' association) and ABIMED/ABIMO (multinational and local manufacturer associations) are useful industry-information sources for BRH and distributor due diligence.

Frequently Asked Questions

Who regulates medical devices in Brazil?

ANVISA (Agência Nacional de Vigilância Sanitária) is the sole national regulator for medical devices, IVDs, and SaMD in Brazil, with authority over classification, notification/registration, BGMP manufacturing-site certification, import licensing, labeling, and post-market vigilance. There is no separate notified-body or third-party certification layer analogous to the EU system — ANVISA itself conducts (or, via MDSAP-report reliance, reviews) the technical assessment.

Does Class II require registration (Registro) or just notification (Cadastro) in Brazil?

Notification (Cadastro) — not Registro. Under RDC 751/2022 Article 6, Classes I and II are both subject to the Notificação regime, with no substantive pre-market technical review and no BGMP requirement. Only Classe III and Classe IV devices are subject to the full Registro regime under Article 7, which does require BGMP certification. This corrects a common misconception (and an error in some published summaries, including a prior version of this page) that only Class I qualifies for the simplified notification track.

What is a Brazil Registration Holder (BRH), and can a foreign manufacturer hold its own registration?

No — a foreign manufacturer cannot hold an ANVISA Cadastro or Registro directly. It must appoint a Brazil Registration Holder (BRH), a Brazilian legal entity holding a valid AFE, to hold the certificate in its name. Unlike some regional peers (for example, Japan's Foreign Special Approval/D-MAH route), Brazil offers no mechanism for the foreign manufacturer itself to retain certificate ownership — the BRH structure choice (owned subsidiary vs. independent regulatory-only BRH vs. distributor-bundled BRH) is therefore a first-order commercial decision.

When is BGMP certification required, and does MDSAP help?

BGMP (Certificado de Boas Práticas de Fabricação) certification is required for Classe III and Classe IV medical device and IVD manufacturing sites as a precondition of Registro approval — it is not required for Classe I/II Notificação. Yes, MDSAP helps directly: ANVISA is an MDSAP founding regulatory authority, and where a manufacturer holds a current MDSAP certificate, ANVISA uses the MDSAP audit report to support the BGMP certification decision and may waive its own on-site inspection; MDSAP certification also extends BGMP validity from the 2-year default to 4 years under RDC 850/2024.

Does an existing FDA or CE approval speed up ANVISA registration?

Only FDA (and, equally, Health Canada, Australia's TGA, and Japan's MHLW) formally does — CE does not. Under the RDC 741/2022 Regulatory Reliance pathway, operationalized by IN 290/2024, Classe III/IV device and IVD registration petitions can use an "optimized analysis" procedure when the product already holds approval from one of four recognized Equivalent Foreign Regulatory Authorities (AREE): the US FDA, Health Canada, Australia's TGA, or Japan's MHLW. The EU (CE Mark, MDR or MDD) and China's NMPA are not currently on this list. CE technical documentation still has informal value — its structure eases reorganization into ANVISA's IMDRF-aligned dossier format — but it does not trigger the formal reliance mechanism, any confirmed timeline reduction, or any fee discount.

How long does Brazil medical device registration actually take, end to end?

Realistic ranges by pathway: 1–3 months for a Classe I/II Cadastro; 18–30 months for a standard Classe III Registro; 36–60+ months for a Classe IV Registro, with complex devices (implants, genuinely novel technology) sometimes exceeding 5 years. Each Exigência round adds several months to over a year, and — for Class III/IV — BGMP inspection queueing runs in parallel and can independently pace the timeline, especially for manufacturing sites without a usable MDSAP audit report.

How long is an ANVISA registration valid, and what does renewal require?

Cadastro (Classe I/II): indefinite, with no revalidation requirement, subject to the BRH's own AFE annual renewal. Registro (Classe III/IV): 10 years, renewable for successive 10-year periods — the Renovação petition must be filed at least 6 months before expiry, and must include updated PSUR data and any accumulated Alteração history. BGMP certificates run on their own separate 2-year cycle (4 years with MDSAP), independent of the underlying Registro's 10-year clock — a lapsed BGMP certificate can block imports even while the Registro itself remains formally valid.

What special requirements apply beyond the core ANVISA registration?

Three parallel tracks commonly apply beyond the core Cadastro/Registro process: Portuguese-language labeling and IFU (mandatory for all classes); INMETRO certification for electro-medical devices (based on ABNT/IEC standards, administered independently of ANVISA); and ANATEL homologation for any device with wireless/RF connectivity (mandatory before lawful commercialization, including SAR testing for body-worn devices). A connected electro-medical device needs all three running in parallel from the start of dossier preparation, not sequentially after ANVISA approval.

Official Sources and Verification Dates

• ANVISA — official portal: https://www.gov.br/anvisa/pt-br (accessed 2026-08-17)
• ANVISA — SOLICITA electronic filing system: https://solicita.anvisa.gov.br (accessed 2026-08-17)
• ANVISA — NOTIVISA adverse-event/field-action reporting system: https://notivisa.anvisa.gov.br (accessed 2026-08-17)
• ANVISA — Regulatory Reliance (Confiança Regulatória), official international-position page (directly fetched): https://www.gov.br/anvisa/en/international-position/regulatory-reliance (fetched and confirmed 2026-08-17; AREE list — FDA, Health Canada, TGA, MHLW/PMDA — cross-checked here)
• ANVISA — Certificado de Boas Práticas de Fabricação (CBPF), official FAQ (directly fetched): https://www.gov.br/anvisa/pt-br/acessoainformacao/perguntasfrequentes/administrativo/certificados-de-boas-praticas/cbpf (accessed 2026-08-17; BGMP 2-year base validity and company-linkage/non-transferability confirmed here)
• ANVISA — RDC 751/2022 official legislative text (Datalegis, directly fetched): https://anvisalegis.datalegis.net/action/ActionDatalegis.php?acao=abrirTextoAto&tipo=RDC&numeroAto=00000751&seqAto=000&valorAno=2022&orgao=RDC/DC/ANVISA/MS (fetched and confirmed 2026-08-17; Article 6/7 Notificação/Registro class split, Article 11 10-year validity, Article 14 BGMP precondition cross-checked here)
• ANVISA — "Perguntas & Respostas" RDC 751/2022 official Q&A: https://www.gov.br/anvisa/pt-br/centraisdeconteudo/publicacoes/produtos-para-a-saude/manuais/perguntas-respostas-rdc-751-de-2022 (accessed 2026-08-17)
• RDC 830/2023 official legislative text (Datalegis): https://anvisalegis.datalegis.net/action/ActionDatalegis.php?acao=abrirTextoAto&tipo=RDC&numeroAto=00000830&seqAto=000&valorAno=2023&orgao=RDC/DC/ANVISA/MS (accessed 2026-08-17)
• ANVISA — official news release on RDC 830/2023 IVD update: https://www.gov.br/anvisa/pt-br/assuntos/noticias-anvisa/2023/anvisa-atualiza-regras-sobre-dispositivos-medicos-para-diagnostico-in-vitro (accessed 2026-08-17)
• RDC 657/2022 (SaMD) official Q&A (directly referenced): https://www.gov.br/anvisa/pt-br/assuntos/noticias-anvisa/2022/software-como-dispositivo-medico-perguntas-e-respostas/perguntas-respostas-rdc-657-de-2022-v1-01-09-2022.pdf (accessed 2026-08-17)
• RDC 741/2022 official legislative text (Datalegis): https://anvisalegis.datalegis.net/action/ActionDatalegis.php?acao=abrirTextoAto&tipo=RDC&numeroAto=00000741&seqAto=000&valorAno=2022&orgao=RDC/DC/ANVISA/MS (accessed 2026-08-17)
• RDC 551/2021 official legislative text (Datalegis): https://anvisalegis.datalegis.net/action/ActionDatalegis.php?acao=abrirTextoAto&link=S&tipo=RDC&numeroAto=00000551&seqAto=000&valorAno=2021&orgao=RDC/DC/ANVISA/MS (accessed 2026-08-17; 10-day/30-day field-action notification windows and Level I/II/III recall classification cross-checked here)
• Emergo by UL — "Brazil ANVISA Legislation Allows Leveraging Regulatory Authorizations for Medical Devices" (directly fetched, specialist medtech regulatory-services analysis of RDC 741/2022 and IN 290/2024): https://www.emergobyul.com/news/brazil-anvisa-legislation-allows-leveraging-regulatory-authorizations-medical-devices (fetched and confirmed 2026-08-17; four-authority AREE list, Class III/IV-only scope, and CE exclusion independently cross-checked here)
• Emergo by UL — MDSAP updates and Brazil requirement analysis: https://www.emergobyul.com/news/mdsap-updates-and-possible-requirement-brazil (accessed 2026-08-17)
• Emergo by UL — Brazil GMP certificate extension to four years: https://www.emergobyul.com/news/extension-brazil-gmp-certificates-four-years-official (accessed 2026-08-17; RDC 850/2024 4-year BGMP-with-MDSAP validity cross-checked here)
• Emergo by UL — Brazil Registration Holder (BRH) service description: https://www.emergobyul.com/services/brazil/brazilian-registration-holder (accessed 2026-08-17)
• Global Regulatory Partners — Transfer of Ownership of Registrations at ANVISA (BRH/Titular transfer mechanics, RDC 102/2016 framework): https://globalregulatorypartners.com/transfer-of-ownership-of-registrations-at-anvisa/ (accessed 2026-08-17)
• Machado Meyer — "Anvisa publica regras de Regulatory Reliance para dispositivos" (Brazilian law-firm client alert on RDC 741/2022/IN 290/2024, independently confirming the four-authority AREE list and CE exclusion): https://www.machadomeyer.com.br/pt/inteligencia-juridica/publicacoes-ij/life-sciences-e-saude/anvisa-publica-regras-de-regulatory-reliance-para-dispositivos (accessed 2026-08-17)
• ElendiLabs — RDC 751/2022 classification and regime summary: https://elendilabs.com/en/articles/bra-temas-em-destaque (accessed 2026-08-17)
• Rabelo Maurer Advocacia — RDC 830/2023 IVD summary: https://rabelomaurer.com.br/blog/publicada-nova-rdc-830-2023-sobre-regras-sobre-dispositivos-medicos-para-diagnostico-in-vitro-in-vitro-diagnostics-ivd/ (accessed 2026-08-17)
• Vera Rosas Regulatory Affairs — RDC 657/2022 SaMD summary: https://www.verarosas.com.br/noticias/rdc-657-2022-regularizacao-de-software-como-dispositivo-medico-samd (accessed 2026-08-17)
• LegisWeb — RDC 857/2024 TFVS collection procedure, company-size discount tiers: https://www.legisweb.com.br/legislacao/?id=458768 (accessed 2026-08-17)
• Freyr Solutions — Brazil Registration Holder services: https://www.freyrsolutions.com/medical-devices/brazil-registration-holder (accessed 2026-08-17)
• MedDeviceGuide — Brazil ANVISA medical device cost breakdown and LATAM comparison (2026 guides, secondary cost benchmarking): https://meddeviceguide.com/blog/brazil-anvisa-medical-device-cost-breakdown-2026-guide, https://meddeviceguide.com/blog/latam-medical-device-registration-comparison-guide (accessed 2026-08-17)
• ANVISA — 2026–27 Regulatory Agenda official hub / announcement: https://www.gov.br/anvisa/pt-br/assuntos/regulamentacao/agenda-regulatoria (reference added 2026-08-18 from the supplied industry brief; not directly fetched in this no-network update)
• IMDRF — Brazil forum material cited for MDSAP/BGMP figures: https://www.imdrf.org/sites/default/files/2026-03/Brazil.pdf (reference added 2026-08-18 from the supplied industry brief; direct content verification pending)
• ANVISA — IN 426/2026 official-number record (SIUD implementation of RDC 591/2021): https://anvisalegis.datalegis.net/action/ActionDatalegis.php?acao=abrirTextoAto&tipo=IN&numeroAto=00000426&seqAto=000&valorAno=2026&orgao=RDC/DC/ANVISA/MS (reference added 2026-08-18; URL follows the official Datalegis record convention and was not fetched in this no-network update)
• Source-level note for the three entries above: the facts added in this update come from an industry report that cites official instrument numbers; direct verification of the official originals is scheduled for the monthly review.
• Verification date: 2026-08-18

Items Flagged for Further Verification (【待核验】)

• Exact current ANVISA TFVS fee schedule by class, petition code, and company-size tier — the BRL/USD figures in the Quick Reference and Element 5 combine figures carried over from the prior version of this page with secondary regulatory-services benchmarks; the official ANVISA TFVS rate table was not exhaustively fetched line-by-line during this verification pass.
• The specific BGMP (CBPF) certification/inspection TFVS fee amount for a foreign manufacturing site — confirmed as a distinct petition code and fee event, but the current reais value was not independently verified.
• The precise, quantified review-time reduction attributable to the RDC 741/2022 AREE reliance pathway (cited by secondary sources as roughly 30%) — no official ANVISA quantification of this figure was located; treat as a directional, not contractual, benchmark.
• Whether "Análise Prioritária" (priority review) and the "TEF (Termo de Especificação Funcional)" early-engagement mechanism, as described in the prior version of this page, apply to medical devices specifically (as opposed to, or in addition to, medications/medicamentos, where a distinct and better-documented priority-analysis mechanism under RDC 204/2017 and RDC 811/2023 clearly exists) — this could not be independently confirmed for devices during this research pass and is carried forward with an explicit flag rather than being asserted as verified.
• Whether the classification-and-regime split confirmed here (Class I/II Notificação vs. Class III/IV Registro, RDC 751/2022 Articles 6/7/11/14) has been amended by any RDC published after this verification date; RDC 751/2022 has already been subject to periodic manual updates (most recently referenced in a 2025 ANVISA manual republication) since its 2023 entry into force.
• Ordinance No. 1.484/2025 agenda item 5.6, the RIA-to-publication sequence, the 1–2 year implementation estimate, and the reported 59–61% MDSAP share of BGMP certificates — official instruments/materials cited via the supplied industry report; direct official verification remains pending.
• IN 426/2026 SIUD effective date, the four class-specific data-submission deadlines, and the five BRH operating requirements — official instrument number via the supplied industry report; direct official-text verification remains pending.
• The 1 July 2026 WHO tWLA-MD first-list composition and its 12 named authorities/networks — WHO material via the supplied industry report; direct WHO-source verification remains pending.
• The February 2026 registration total, China-origin share, AnvisAI budget, and reviewer-headcount figures — ANVISA figures/program details via the supplied industry report; direct official verification remains pending.